News release:
THE IMMUNE RESPONSE CORPORATION ANNOUNCES REMUNE CLINICAL TRIAL IN
SOUTH AMERICA
CARLSBAD, Calif., Aug 12, 1999 /PRNewswire via COMTEX/ -- The Immune Response Corporation (Nasdaq: IMNR) today announced its Latin American corporate partner, Roemmers Laboratory (formerly Viru-Tech), is conducting a REMUNE(TM) Phase 2 clinical trial in South America. This 28-week clinical trial is being conducted by GEMA (Grupo de Estudios Multicentricos en Argentina) at three clinical centers in Buenos Aires, Argentina under the direction of Dr. Pedro Cahn, a leading infectious disease expert in South America. "The urgency of an HIV treatment with the potential of enhancing a patient's immunity is based on the increasing number of drug failures and the possibility to treat large numbers of patients not taking drugs," said Dr. Cahn. This double-blind placebo-controlled trial is expected to enroll up to sixty patients and will examine the effect of REMUNE on HIV specific immune function and viral load in asymptomatic HIV-1 infected individuals.
This is the first clinical trial conducted using REMUNE in South
America, where an estimated 1.4 million people are infected with the
HIV-1 virus. Other clinical trials currently being conducted outside
the U.S. using REMUNE include a 243-patient Phase 2 trial being
conducted in Spain to study viral load, CD4 levels and immune function, and a 300-patient Phase 2 trial with similar endpoints nearing completion in Thailand. Several smaller clinical trials are also being conducted in Europe and the United States in combination with other HIV therapies. A U.S. Phase 3 pivotal trial to be conducted in collaboration with Agouron Pharmaceuticals, Inc., a wholly owned subsidiary of Warner-Lambert Company, (NYSE: WLA), is expected to commence enrollment this quarter.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce
specific T-cell responses for the treatment of HIV and autoimmune
diseases. In addition, the Company is working on cancer vaccines and
gene therapy.
|
